COLL analyst estimates
Collegium (COLL) analyst ratings, the average price target and its range, and every firm's latest call.
COLL analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Collegium Pharmaceutical initiated with an Outperform at Oppenheimer | $50.00 |
| Sep 9, 2026 | Truist Financial | Collegium Pharmaceutical assumed with a Buy at Truist | $49.00 |
| Sep 9, 2026 | Leerink Partners | Collegium Pharmaceutical initiated with an Outperform at Leerink | $45.00 |
| Aug 19, 2026 | Barclays | Collegium Pharmaceutical price target lowered to $48 from $56 at Barclays | $48.00 |
| Feb 10, 2026 | Truist Financial | Collegium Pharmaceutical price target raised to $58 from $55 at Truist | $58.00 |
| Jan 9, 2026 | H.C. Wainwright | Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright | $60.00 |
| Jan 9, 2026 | Barclays | Collegium price target lowered to $56 from $58 at Barclays | $56.00 |
| Jan 7, 2026 | Truist Financial | Collegium Pharmaceutical price target raised to $55 from $47 at Truist | $55.00 |
| Dec 8, 2025 | Barclays | Collegium Pharmaceutical initiated with an Overweight at Barclays | $58.00 |
| Feb 4, 2025 | Piper Sandler | Collegium Pharmaceutical price target lowered to $36 from $37 at Piper Sandler | $36.00 |
| Nov 11, 2024 | Jefferies | Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies | $40.00 |
| Sep 4, 2024 | H.C. Wainwright | Collegium Pharmaceutical price target raised to $50 from $47 at H.C. Wainwright | $50.00 |
| Aug 9, 2024 | Piper Sandler | Collegium Pharmaceutical (COLL) PT Lowered to $37 at Piper Sandler | $37.00 |
| Jul 30, 2024 | H.C. Wainwright | H.C. Wainwright Upgrades Collegium Pharmaceutical (COLL) to Buy | $47.00 |
| Jun 7, 2024 | Jefferies | Jefferies Upgrades Collegium Pharmaceutical (COLL) to Buy | $44.00 |
- 7 firms rate COLL: 6 buy, 1 hold, 0 sell.
- The average price target is $48.00 from 4 analysts, from $45.00 to $50.00.
Updated 2026-11-03 11:31 UTC